Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010)

JAMA Internal Medicine

Volumn 174, Issue 5, 2014, Pages 699-707

  Winkelmayer, Wolfgang C ^a   Mitani, Aya A ^a   Goldstein, Benjamin A ^a   Brookhart, M Alan ^b   Chertow, Glenn M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FERRIC GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ALBUMIN BLOOD LEVEL; ANEMIA; BLOOD TRANSFUSION; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DIALYSIS; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; IRON THERAPY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; COHORT STUDIES; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBIN A; HUMANS; INCIDENCE; IRON; KIDNEY FAILURE, CHRONIC; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; RECOMBINANT PROTEINS; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84899799050     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.87     Document Type: Review

References (29)

1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28(1):1-5.
2. Hsu CY,McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J AmSoc Nephrol. 2002;13(2):504-510.
3. Zipf RE Jr. Fatal anaphylaxis after intravenous iron dextran. J Forensic Sci. 1975;20(2):326-333.
4. Novey HS, Pahl M, Haydik I, Vaziri ND. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72(3):224-228.
5. Buchwald D, Argyres S, Easterling RE, et al. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron. 1977;18(4):232-238.
6. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992-1000.
7. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30(4)(suppl 3):S192-S240.
8. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis. 2008;52(6):1115-1121.
9. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590.
10. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
11. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
12. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
13. Ishida JH, McCulloch CE, Dudley RA, Grimes BA, Johansen KL. Dialysis facility profit status and compliance with a black box warning. JAMA Intern Med. 2013;173(12):1152-1153.
14. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J AmSoc Nephrol. 2012;23(12):2042-2049.
15. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706.
16. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
17. WinkelmayerWC, Liu J, Chertow GM, Tamura MK. Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med. 2011;171(15):1371-1378.
18. Carson JL, Grossman BJ, Kleinman S, et al; Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49-58.
19. Ibrahim HN, Ishani A, Guo H, Gilbertson DT. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. Nephrol Dial Transplant. 2009;24(10):3138-3143.
20. Gill KS, Muntner P, Lafayette RA, et al. Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28(6):1504-1515.
21. Hakim RM, Stivelman JC, Schulman G, et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis. 1987;10(4):293-299.
22. Yabu JM, AndersonMW, Kim D, et al. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant. 2013;28(11):2908-2918.
23. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10(1):26-29.
24. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J AmSoc Nephrol. 2010;21(8):1398-1406.
25. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5)(suppl 3):S16-S85.
26. Whitman CB, Shreay S, Gitlin M, van Oijen MG, Spiegel BM. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J AmSoc Nephrol. 2013;8(11):1942-1951.
27. Gilbertson DT, Monda KL, Bradbury BD, Collins AJ. RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL. Am J Kidney Dis. 2013;62(5):919-928.
28. United States Renal Data System. Clinical indicators and preventive health. In: USRDS 2010 Annual Data Report: Atlas of End-Stage Renal Disease and Chronic Kidney Disease in the United States - Vol. 2: Atlas of End-Stage Renal Disease. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011:287-300.
29. US Food and Drug Administration. FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. 2011. http://www.fda.gov/drugs /drugsafety/ucm259639.htm. Accessed August 26, 2013.